Skip to main content
Back to Resources

Supporting Cancer Care During COVID-19

We understand the impact COVID-19 continues to have on each practice and the challenges healthcare providers may be faced with when delivering patient care. We have taken steps to ensure our labs are open and operational so we can fulfill our responsibility to cancer patients.

Operational Readiness

Currently, all our labs remain open and operational. We have proactively implemented enhanced measures in order to continue to keep our labs operational, such as:

  • Separated lab personnel into different shifts to reduce the risk of cross contamination between lab teams

  • Increased sanitation efforts during and between shifts

  • Restricted access, allowing only employees essential for laboratory operations at our laboratory facilities

  • Enhanced lab process flows to mitigate contamination

  • Increased personal protective equipment where necessary for increased protection

Access to Testing

We know that a cancer diagnosis will not stop for COVID-19. Please consider the following options that may help remove barriers to testing during this time:

FoundationOne®Liquid CDx

  • Our liquid biopsy test may be useful when a patient is unable to undergo a biopsy.

  • We have prepared our laboratories to support additional FoundationOne Liquid CDx orders.

Mobile Phlebotomy

  • Foundation Medicine will continue to offer in-home blood draw services through our mobile phlebotomy partner, ExamOne®, to support broader access to FoundationOne Liquid CDx. ExamOne® has over 6,000 licensed phlebotomists and offers appointments 7 days a week (Monday-Sunday) during the hours of 7:00am-7:00pm.

Financial Assistance Program

Financial assistance is available for qualifying patients in the United States (US) who have out-of-pocket costs associated with Foundation Medicine testing. Financial assistance is based on need and can be applied for at any point during the testing process. Payment plans may also be available. Foundation Medicine's financial assistance program is only available to patients whose tests were ordered within the US and US territories.

A financial assistance application (FAA) can be filled out online or by contacting our Client Services team at:

Phone: 888.988.3639

Email: client.services@foundationmedicine.com

If a patient experiences a change in their financial status, they can re-apply by updating their financial assistance application form and/or by submitting additional documents documenting the changes or new information.

Our Commitment to the Community

Foundation Medicine is thankful to those fighting COVID-19 on the front lines and we are committed to assisting our national partners and local communities. Through our initiative, FMI Helps, Foundation Medicine is providing nearly $500K in ongoing charitable support to cancer nonprofits committed to addressing critical needs of those living with cancer during COVID-19 and to local community organizations providing vital support in Boston, Raleigh, San Diego and Penzberg, where Foundation Medicine labs and operations are present

To view information on how our partners at Roche are responding to COVID-19, please visit their response page on roche.com.

Need More Details?

Our client services team is here to help, Monday through Friday 8AM – 8PM EST. 

Contact Us

Important Safety Information

Select

FoundationOne Liquid CDx

FoundationOne®Liquid CDx is for prescription use only and is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors. The test analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes and as a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 of the Intended Use) in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Patients who are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and complete risk information, please visit www.F1LCDxLabel.com.